118 filings
Page 2 of 6
8-K
qifujxw2jtn 62167
4 May 23
Regulation FD Disclosure
4:07pm
8-K
rwhpj4m3479xq88etj
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
9:05am
8-K
x7i3yqkvqumpmfwr ev0
4 May 23
X4 Pharmaceuticals Reports First-Quarter 2023 Financial
6:42am
8-K
xrj4fu19
21 Mar 23
Regulation FD Disclosure
5:02pm
8-K
nl4o8iv
21 Mar 23
X4 Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial
7:09am
8-K
gwncl
10 Mar 23
Other Events
4:05pm
8-K
9pg kiqvv
6 Jan 23
Entry into a Material Definitive Agreement
5:26pm
8-K
9vqkv6m
5 Jan 23
Regulation FD Disclosure
4:10pm
8-K
9jk0b0 1q
23 Dec 22
Departure of Directors or Certain Officers
4:02pm
8-K
u0pvb9e
9 Dec 22
X4 Pharmaceuticals Announces Proposed Public Offering
8:46am
8-K
9xliuve77clybr
29 Nov 22
X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome
4:05pm
8-K
fmgb15x7v
9 Nov 22
Departure of Directors or Certain Officers
4:18pm
8-K
ffijr0 12c4njeiq
3 Nov 22
X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:21am
8-K
5rskhxg1sl
4 Oct 22
Regulation FD Disclosure
4:42pm
8-K
1d2bu5hchv
27 Sep 22
Regulation FD Disclosure
7:53am
8-K
fzqm2z jmzs1
1 Sep 22
Material Modifications to Rights of Security Holders
4:51pm
8-K
tkp1vrp2pc
5 Aug 22
Regulation FD Disclosure
8:10am
8-K
0hykjog832vc608n8
4 Aug 22
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:29am
8-K
w7hca1mnn cy6nl9k
29 Jul 22
Departure of Directors or Certain Officers
4:05pm
8-K
8ammntv
1 Jul 22
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months
4:34pm